Genenta Science and Anemocyte expand collaboration to advance off-the-shelf LVV Plasmid DNA platform
Genenta Science, a pioneer in immuno-oncology, and Anemocyte, a leading provider of advanced therapy and nucleic acid solutions, have announced an expanded strategic collaboration focused on developing an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform.
Anemocyte | 27/10/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy